Utah-based nutrition technology firm accomplishes what few major global tech companies have done: achieving a 3-for-3 “All-A, All-Yes” result on international search reports; WIPO applications released today.
WOODS CROSS, UT, UNITED STATES, July 23, 2026 /EINPresswire.com/ — IndulgeRx Brands Inc. (“IndulgeRx”), a privately held nutrition technology enterprise funded by its founder and friends & family, announced today that the World Intellectual Property Organization (WIPO) has formally published all three of its Patent Cooperation Treaty (PCT) patent applications related to its AI-driven IRX FOODSCORE® platform. Each application individually received an “all-A” International Search Report (ISR) from the U.S. International Searching Authority (ISA/US), with every claim deemed novel, inventive, and industrially applicable.
The Details of the Achievement
Every patent application in the AI or health-tech space undergoes review by a professional patent examiner who searches globally for prior inventions that might block or duplicate the claims. Citations are categorized: “X” indicates a discovery that could kill the invention, “Y” shows that a combination of existing concepts could undermine the claims, and “A” represents background information that poses no real threat to patentability.
Across all three IndulgeRx filings—covering the platform as a system, as software, and as a business method—the examiner found zero “X” and zero “Y” citations. Every reference returned an “A” grade, and each Written Opinion confirmed novelty, inventive step, and industrial applicability for claims 1 through 15.
The government (ISA) patent examiner’s own written conclusions highlight the significance of this outcome: even after merging every piece of prior art the examiner could locate, the reviewer determined that combining them “would be impermissible hindsight,” a patent term meaning reverse-engineering a solution only possible when looking backward. Additionally, where existing technology touched on isolated elements of the puzzle, the examiner found that merging them “would not provide any advantages over the present application, or would require a complexity beyond the level of ordinary skill.”
Each published application is now available for public viewing via WIPO PATENTSCOPE:
• IRX FS SOFTWARE – WO2026156106 A1
• IRX FS METHOD – WO2026156110 A1
• IRX FS SYSTEM – WO2026156104 A1
Perspectives on the Milestone
“For a nine-year, self-funded company to enter the same global patent examination process that Google, Amazon, and Oracle undergo, and to exit with a cleaner search result than most well-funded startups ever achieve, is validation that money cannot buy,” said John L. Hastings III, CEO and Founder of IndulgeRx Brands Inc. “IRX FOODSCORE® is not a feature layered onto someone else’s technology. It is genuinely novel, and now the world can see that for itself; changing the way the world eats, one byte at a time.”
“An independent patent examiner tested IRX’s technology against the biggest names in health AI, including Medtronic, Oracle, Salesforce, Cornell, and others, and could not find any single reference or combination that overcomes it,” said Richard D. Clarke, Esq., IndulgeRx’s patent counsel. “That is now a matter of public WIPO record, with a locked priority date of January 16, 2025 that predates every future copycat.” Patent counsel further notes that one filing required a minor procedural claim-grouping clarification that did not affect the ‘A’ grades or any novelty findings, simply underscoring that this achievement rests on substance, not a technicality.
Significance for All Types of Investors
For IRX friends, family, and individual supporters who funded this company from the start, this represents independent, government-verified proof that a small, mission-driven team can out-innovate giants with far greater resources. For institutional investors and strategic acquirers, this milestone substantially de-risks the IP moat that supports IndulgeRx’s twelve monetizable vantage points: consumer apps, CPG licensing, retail, payers and providers, pharmacists, sports performance, researchers, and government agencies. It also bolsters the company’s value propositions and market positioning ahead of seed round and Series A investment discussions and strategic partnership conversations.
IRX FOODSCORE® examines an individual’s health history, age, gender, medications, and goals against ingredients, additives, preservatives, and preparation methods to produce two personalized numbers: a Relevant Nutrition Score (RNS) and a Relevant Risk Score (RRS), turning “is this good for me?” into one actionable IRX FOODSCORE® answer, anywhere in the world.
For additional details about IndulgeRx Brands Inc. and IRX FOODSCORE®, visit www.indulgerx.com and www.indulgerx.com/irx-foodscore, or www.fightbackfoods.com.
Joe Darnell
IndulgeRx Brands, Inc
+1 801-683-8769
email us here
